metabolic disease

08.11.2024 • News

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

11.05.2016 • News

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

08.11.2015 • News

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Virtual Event

CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

metabolic disease

Ascendis Licences Proprietary Technology to Novo Nordisk

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

20 Years of CHEManager International

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

A successful concept on course for expansion — maintenance Munich 2025

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Virtual Event

Digitalization in the Chemical Industry

Newsletter & e-edition